Anaphylaxis
Risk of severe allergic reaction. Seek urgent medical help if serious symptoms occur.
Leaflet MABCAMPATH 30mg / ml concentrate for solution for infusion
- Product code:
- W42669001
- Quantity:
- 3
- Indicated for:
- multiple sclerosis; chronic lymphocytic leukemia
- Route of administration:
- infusion
- Substance:
- alemtuzumab (monoclonal antibody)
- ATC
- L01XC04 — Antineoplastic and immunomodulating agents | Other antineoplastic agents | Monoclonal antibodies
Precautions:
Avoid live vaccines
Avoid live vaccines during treatment if contraindicated.
Immunosuppression / infection risk
This medicine may increase the risk of infections.
Additional monitoring
This medicine is subject to additional monitoring.
Breastfeeding warning
Use during breastfeeding only on medical advice.
Pregnancy warning
Use during pregnancy only on medical advice.
Alemtuzumab is a monoclonal antibody used for the treatment of relapsing multiple sclerosis and chronic lymphocytic leukemia (CLL). It works by targeting the CD52 protein on the surface of lymphocytes, destroying cells involved in autoimmune or cancerous responses.
It is administered via intravenous infusion, usually in cycles, under the supervision of a specialist. Alemtuzumab is commonly used in patients who do not respond to other treatments or have severe forms of the disease.
Side effects may include infusion reactions, infections, fever, fatigue, or autoimmune disorders. In rare cases, severe reactions such as kidney damage or opportunistic infections may occur.
Patients should be closely monitored before, during, and after treatment to identify any adverse reactions. It is essential to follow the doctor's recommendations to minimize risks and optimize treatment benefits.
It is administered via intravenous infusion, usually in cycles, under the supervision of a specialist. Alemtuzumab is commonly used in patients who do not respond to other treatments or have severe forms of the disease.
Side effects may include infusion reactions, infections, fever, fatigue, or autoimmune disorders. In rare cases, severe reactions such as kidney damage or opportunistic infections may occur.
Patients should be closely monitored before, during, and after treatment to identify any adverse reactions. It is essential to follow the doctor's recommendations to minimize risks and optimize treatment benefits.
General data about MABCAMPATH 30mg / ml
- Substance:
- alemtuzumab
- Date of latest medicines list:
- 01-07-2013
- Product code:
- W42669001
- Concentration:
- 30mg / ml
- Pharmaceutical form:
- concentrate for solution for infusion
- Quantity:
- 3
- Product type:
- Original
- Prescription status:
- S — Medicines dispensed with a restricted medical prescription, reserved for use in certain specialized fields.
Concentrations available for alemtuzumab
- 10mg/ml
- 12mg/1.2ml
- 30mg/ml